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Two quite different  methods of inducing histamine release from rat peritoneal 
mast ceils have been described (1, 2). The first is the nonsemm requiring, homo- 
cytotropic antibody-mediated release of histamine examined in the preceding 
paper;  the antigen-antibody-activated esterase  involved in this reaction has 
been distinguished from the first component of rat complement (3). In the sec- 
ond method, histamine is  released  when serum is  added to cells previously 
sensitized with rabbit anti-rat gamma globulin rabbit anti-RGG. Sensitization 
results from the interaction of rabbit anti-rat IgG with rat IgG on the surface 
of the mast cell (2). 
The factors in normal serum required for the latter reaction are inactivated 
by heating to 56°C for 30 rain, by the presence of ethylenediaminetetraacetate 
(EDTA), and by prior absorption with an unrelated antigen-antibody  aggregate 
(1). These findings are consistent with the view that the serum factors are com- 
plement, but there is no apparent correlation between the histamine-releasing 
activity of serum from different species and their content of hemolytic comple- 
ment (1, 4). Moreover, Keller (5) showed that rabbit serum genetically  deficient 
in the sixth component of complement would sustain histamine release (6) and 
concluded that not all the components of complement are required. On the basis 
of results obtained with the classical complement R reagents, he considered that 
activation of the first component of complement was necessary  but that the 
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second component of complement was not involved (4, 5) in the release of his- 
tamine by rabbit anti-rat gamma globulin. 
Most previous investigations have sought to relate complement causally to a 
biologic activity other than immune hemolysis by removing one or another of 
the components of complement and then testing the resulting "reagent" for the 
biologic activity in question. A reduction in biologic activity is taken as proof 
for the requirement of a  given component of hemolytic complement. This is 
obviously a necessary condition for concluding that complement is involved; in 
view of the unspecific nature of the procedures for removing complement com- 
ponents, it is not, however, a sufficient condition. In the present investigation 
it was deemed necessary to fulfill two conditions before concluding that a given 
component of complement was required: (a) a reagent lacking in this component 
must not sustain histamine release; and (b) the histamine-releasing capacity of 
the reagent must be restored by the addition of the isolated, purified component 
in question. 
The second aspect of this investigation was the study of the pattern of in- 
hibition  by  p-nitrophenylethyl  phosphonate  esters  of  histamine  release  by 
rabbit  anti-RGG.  For  comparison,  the  activity  of  the  phosphonate  esters 
against the activated first component (Cqa)  of rabbit complement bound  to 
sensitized sheep erythrocytes was also determined. 
The results obtained have permitted the following comparisons: (a) the spe- 
cific complement components involved in the complement-dependent, noncyto- 
toxic release of histamine have been compared with those required for immune 
hemolysis; and (b) a phosphonate-sensitive, antigen-antibody-activated ester- 
ase essential to the complement-dependent, release of histamine by rabbit anti- 
RGG has been compared with the first component of complement and with the 
esterase involved in homocytotropic antibody-mediated release of histamine. 
Materials and Methods 
Complement.--Fresh or fresh frozen normal human or rabbit sera were used as sources of 
whole complement. The sera were dialyzed against 500 ml of glucose-free. Tyrode's buffer, 
which was changed 3 times over a 6 hr period. 
Purified Complement Components.--First component of human complement (C'I) was re- 
constituted  by the combination of the subcomponents, C'lq, C'lr, and  C'ls (W.R.U., 29 
October 1965) kindly supplied by Dr. Irwin H. Lepow (7, 8). Highly purified human second 
component of complement (C'2) containing EDTA 10  -8 M and dithioerythritol 10  -4 M was 
obtained from Dr.  Lepow (9); Dr.  Hans Miiller-Eberhard supplied a highly purified C~2 
preparation  (20, 190/~g protein per ml) which had not been activated by exposure to molec- 
ular iodine (10). The components C'3 (162 II; C-184 III), (11, 12), C'4 (30, pool 2; 34) (13), 
and C'5 (B 40; B 49) (11) were generously made available by Dr. Miil]er-Eberhard. 
Complement Reagents.--The R1 reagent, human serum deficient in the first component of 
complement (Cq), was prepared by dialysis according to Mayer (14). The reagent was forti- 
fied either with an equal volume of serum previously heated for 20 min at 56°C (R1 +  H) or 
with highly purified C'3, C'4, and C'5 (R1 +  C'3 +  C'4 +  C'5) in concentrations of 790, 
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Certain reagents were sera from men or animals with an inborn or acquired, selective deft- 
ciency of a single component of complement. C'2-deficient sera were obtained from 2 siblings 
with a  genetic deficiency in the second component of complement (15). Sera predominantly 
deficient in C'3 were obtained from 2 patients with renal disease; these sera were furnished by 
Dr. Fred Rosen (16). Sera from rabbits with a genetic deficiency in C'6 (6, 17) were supplied 
both by Dr. Klaus Rother and by Dr. Carlos Biro and Dr. Charles C.  Cochrane. 
Human sera deficient in C'3 and C'4 or in C'3, c'g, and C'5 were prepared by treatment 
with 0.5 ~  or 1.0 ~s KSCN respectively, followed by exhaustive dialysis (18). These two rea- 
gents were supplied by Dr. Miiller-Eberhard. 
Material for InMbigtm  St~ie~.--The  buffers and  the p-nitrophenylethylalkyl, phenyl- 
alkyl, chloroaikyl, and aminoalkyl phosphonates were those previously described (3). Partially 
purified rabbit C'la was isolated from rabbit serum in the same manner as rat C'la (3). The 
red cell intermediate, EAC'la tab, 4 gp was prepared as described for EAC'la  rat, 4 gp except 
for the use of rabbit C'la in place of rat C'la. 
Preparation of Sensitized Mast Cells (MAgAb).--The peritoneal cell suspensions were har- 
vested from rats 10 to 20 wk of age (2). These cells were washed, pooled, and washed again 
(3). The rabbit anti-rat gamma globulin (Ra anti-RGG) 17 used to sensitize the cells has been 
described (1). In a  typical experiment sensitization was achieved by interacting 18 ml of a 
cell suspension (3) for 5 rain at 37°C with an equal volume of Ra anti-RGG diluted 1:375. 
Mter sensitization the cells were washed twice, resuspended in 30 ml Tyrode's-gelatin buffer, 
and stored at 4°C. 
Preparation of Cell in the MAgAbC'la  hu StaCe.--The pool of sensitized cells was  divided 
into equal portions, sedimented, and resuspended in only 0.5 ml iced Tyrode's-gelatin buffer. 
One portion received serially 0.08 ml C'lq, 0.08 ml C'lr, and 0.08 ml C'ls, while the other 
received 0.24 ml of Tyrode's-gelatin buffer. The reaction mixtures were incubated at 37°C for 
5 rain with gentle agitation, diluted with 10 ml buffer, sedimented at 4°C at 400 g for 4 min, 
resuspended in 18 ml Tyrode's-gelatin buffer, and stored at 4°C. 
Reconstitugon of Complement Activity of Complement-Deficient Reagents.--Six,  11  (Miiller- 
Eberhard), and 39 (Lepow) units of C'2 were added to I ml aliquots of the C'2 deficient serum 
to restore its complement activity. Increasing amounts of C'3,  158,  316, and 632/~g, were 
added to 1 mi aliquots of nephritic sera with restoration of hemolytic activity; as a  control 
84/~g of C'4 was added to another aliquot of the same sera. Serum treated with 0.5 ~t KSCN 
to produce a deficiency in C'4 and C'3 was reconstituted by adding 84/~g of C'4 and varying 
ammmts of C'3: 395, 494, 987, or 1974/~g per ml; as a control 84/~g of C'4 and 395 or 494/~g 
of C'3 were added alone. Serum treated with 1.0 M KSCN to produce a deficiency of C'4, C'3, 
and C'5 was restored by adding 151/~g of C'4, 884/~g of C'3, and 104/~g of C'5 per mi; as a 
control only C'3 and C'4 were added to an aliquot of the same reagent. 
Hemolytic Assays.--The  second component of human complement was measured  using 
EAC'la  sp, 4 gp cells as described (19). The assay measures human C'2 as long as human C'4 
is also present in the serum or reagent being titrated (15, 20, 21). 
Whole complement activity, man or rabbit, was assayed by a modification of the procedure 
of Kent et al. (22). The usual 1.5 ml reaction volume (0.6 ml of 2.5 ×  I0  s EA, diluent, and 
complement) was incubated for ~  hr at 37°C, 1 rnl of iced diluent added, the cells sedimented 
by centrifugation, and the supematant fluids decanted and read in a Beckman spectrophotom- 
eter at 540 mu. The optical density of the supernatant fluids was expressed as per cent hemoly- 
sis, plotted in the usual manner to determine the 50% end point, and the CH60 titer calculated. 
In the assay of R1, EAC'la cells were prepared by treating 20 ml of 5 X  l0  s EA with 0.8 ml 
respectively of C'lq,  C'I~. and C'ls added serially. The cells were incubated for 5  rain at 
37°C, sedimented, washed once in iced buffer, and restandardized to 2.5 X  10s cells per ml. 
These cells were then used in the modified Kent procedure as described above. 
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stored at 4°C in Tyrode's-gelatin buffer were divided into 1.0 ml aliquots with a  volumetric 
pipette. The cells were sedimented and resuspended in 2 ml Tyrode's-gelatin. Following pre- 
incubation at 37°C, 0.1 ml of normal rabbit or human serum, complement deficient serum, or 
reconstituted serum was added. The reaction mixture was incubated for 7 rain at 37°C, and the 
cells were then sedimented at 400 g for 4 rain. The superuatant fluid was decanted and assayed 
for histamine; residual histamine in the cells was also determined. Each variable was studied in 
three replicate tubes; two received serum, and the third served as a control for spontaneous 
histamine release. Unsensitized cells from the same pool were always reacted with the source 
of complement to exclude any nonspecific  histamine release by serum alone. Duplicate samples 
gave values for histamine release which varied by less than 3% of the mean value. 
In the experiments concerned with the role of C'la, three different cell preparations were 
used; unsensitized cells,  sensitized cells,  and cells in the MAgAbC'la state. Otherwise, the 
procedure was exactly as described above. 
Inhibition  of Complement-Dependent Histamine  Release by  the Phosphenate  Esters.--The 
pool of mast cells sensitized with rabbit anti-RGG was aliquoted and sedimented as described 
above and then resuspended in 2 ml Tyrode's-gelatin buffer with or without the various phos- 
phonate esters. The solutions of the phosphonate esters were prepared as described (3). Fol- 
lowing preincubation at 37°C,  0.1  ml of rabbit or human  serum was  added as a  source of 
complement. The reaction mixture was incubated 7 rain, and the cells were then sedimented 
at 400 g for 4 rain. The supernatant fluid was decanted and assayed for histamine; residual 
histamine in the cells was also determined. Each variable was studied in three replicate tubes; 
two received serum, and the third served as a control for spontaneous histamine release. 
Enzymatic  Hydrolysis of the Pkosphonale Esters by Rabbit Serum.--The rates of enzymatic 
hydrolysis of the phosphonate esters by rabbit serum were tested as before (23) except that 
Tyrode's buffer was employed and the final concentration of rabbit serum was 5%, the same 
as that used in the complement-dependent  release of histamine by rabbit anti-RGG. 
Inhibitgon of Hemolytic Complement by the Phosphonate Esters.--The inhibition of whole 
rat  and rabbit complement by the phosphonate esters was studied as described (24).  The 
procedure for determining the activity of the various phosphonate esters against rabbit C'la 
was identical to that used in the study of rat C'la (3). 
RESULTS 
Time  Course of Complement-Dependent Histamine Release by  Rabbit Anti- 
RGG.--Histamine could not be detected in the supernatant fluid until  2 rain 
after the addition of rabbit serum to the sensitized cells.  Virtually all  the his- 
tamine was released between the 2nd and 5th rain. 
Requirements for Complement Components 
Requirement for Crla.--The role of C'la was investigated by observing the 
effect of serum deficient in C'la on cells in the MAgAb or MAgAbC'la state 
(Table I). An R1  reagent fortified with  either heated normal human  serum 
(R1 +  H) or highly purified components (R1 +  C'4 +  C'3 +  C'5) gave 12 % 
histamine release from mast ceils in the MAgAbCtla state, whereas R1 or H 
alone failed to release histamine from these cells. These same reagents--R1, H, 
R1 +  H, R1 +  Ct3 +  Cr4 +  C'5--failed to release histamine from cells in the 
MAgAb state because C'la was lacking from the reaction mixture. These re- 
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C'la in the same manner as used in the preparation of MAgAbC'la cells. When 
an EACqa cell was used to measure hemolytic activity, the fortified R1 prep- 
arations had 28 CHs0 units per ml, whereas the R1 alone contained only 3 CHs0 
units per ml. None  of these reagents--R1, H, R1 +  H, R1 +  C'4 +  C'3 + 
C'5--had appreciable hemolytic activity for EA because C'la was lacking from 
the reaction mixture. 
Requirement for C'2.--The role of C~2 was investigated by using serum genet- 
ically deficient in C'2 before and after restoration with highly purified human 
C'2. Neither the deficient nor the reconstituted serum released histamine from 
unsensitized mast cells. The C'2-deficient serum failed to release histamine from 
sensitized cells. With the addition of purified C'2 there was a linear relationship 
between the C'2 units added and the percentage of histamine released (Fig. 1). 
TABLE I 
Role of  C'la  in  Complement-Dependent Histami,  se Rdeoae by Rabbis AnIi-RGG 
C'la present on  Histamine release  Hemolytic titer 
Reagent  cell intermediate  of reagent (CH60) 
Human serum 
Human serum 
R1 
H 
RI+H 
R1  +H 
R1  +  C'4 +  C'3 +  C'5 
R1  +  C'4 +  C'3 +  C'5 
B 
+ 
+ 
+ 
+ 
+ 
% 
21 
24 
0 
0 
0 
12 
0 
12 
135 
162 
3 
0 
3 
28 
4 
28 
* --, MAgAb or EA; and +, MAgAbCqa or EAC'la. 
The relationship held using two different preparations of C'2 purified by differ- 
ent methods (9, 10). 
Requirement for C'3.--The role of C'3 was studied using nephritic sera before 
and after restoration of hemolytic activity with purified human C'3. Neither the 
deficient nor the reconstituted serum released histamine from unsensitized mast 
cells. A deficient serum, even when fortified with C~4, failed to release histamine 
from sensitized cells (Table II). However, the further addition of 316 #g of C~3 
gave 7 % histamine release and raised the hemolytic titer to 39 CHs0 units per 
ml. 
The 7 % histamine release obtained with 0.1 ml of reconstituted nephritic se- 
rum was approximately the same as the release obtained with 0.06 ml of normal 
serum (Table II). In the 0.06 ml normal serum there were 5.5 CH~o units com- 
pared to 3.9 CHs0 units in 0.1 ml of reconstituted serum, indicating a reasonable 
correspondence between restoration of histamine-releasing activity and hemo- 
lyric capacity of the nephritic serum by purified C'3. 402  IMMUNOLOGIC  IN~0"RY.  II 
Requirement for Cr4 and C~3.--The role of C'4 was examined by using 0.5 
KSCN-treated serum, deficient in Ct4 and C'3, before and after restoration of 
hemolytic activity by adding both components. As shown in Table III, experi- 
ment A, neither the addition of Cr4 or CP3 alone restored histamine-releasing or 
hemolytic activity. When both components were added together, hemolytic ac- 
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FIG.  1.  Relationship between per cent histamine released from sensitized mast cells and 
number of C'2 units added to human serum used as a  source of complement in the reaction; 
the serum was genetically deficient in this component. 
tivity was restored, and the reagent gave 12 % histamine release from sensitized 
mast cells. This indicates a need for C'4 as well as C'3 in complement-dependent, 
histamine release. 
In experiment B, the 0.5 ~  KSCN reagent was restored by adding a  fixed 
amount of C~4 and increasing amounts of C~3. Addition of C~4 alone, 84 #g per 
ml, had no effect, whereas the concomitant introduction of 494 and 987/~g of K.  FRAI~K AUSTEN AND ELMER L.  BECKER  403 
C'3 per ml gave 9 and 13 % histamine release, respectively. Increasing the con- 
centration of C'3 to 1974 #g per ml gave no further increment in histamine re- 
lease under these experimental conditions. None of the reagents used in experi- 
ment A and B released histamine from unsensitized mast cells. 
Requirement for C'5.--The role of C'5 was examined by using 1.0 M KSCN- 
treated serum, deficient in C'4, C'3, and C'5. As shown in Table III, experiment 
C, the addition of C'4 and C'3 failed to yield a reagent capable of releasing his- 
tamine from sensitized  cells even when 0.2 ml  as added so  as to give a  final 
concentration of 10 70 rather than the usual 5 70 undiluted serum. The further 
addition of C'5 to this reagent did give 6 70 histamine release. None of the re- 
TABLE II 
Role of C'3 in Complement-Dependent Histamine Rdease by Rabbit Anti-RGG 
Hemolytic titer  Reagent*  Component added:~  Histamine  release  (CH60) 
% 
Normal serum 
0.03 
0.06 
0.12 
Nephritic serum 
0.10 
O. 10 
O. 10 
0.10 
m 
p 
m 
84 #g C'4 
158 #g C'3 
316 #g C'3 
632 #g C'3 
0 
8 
28 
92 
92 
92 
2 
3 
12 
39 
46 
* ml of undiluted serum added to complete reaction volume of 2.0 ml. 
~t Per ml of undiluted serum. 
agents released histamine from unsensitized cells in a final concentration of 10 % 
indiluted serum. 
In another experiment with different preparations of the complement com- 
ponents, the addition of C'4, C'3, and C'5 to 1.0 M KSCN-treated serum yielded 
a reagent which gave 11 70 histamine release. The addition of C'4 and C'3 alone 
or together failed to produce a reagent capable of giving histamine release. In 
this experiment the hemolytic titers of the reagents were not obtained because 
of insufficient  material. 
Inhibition by Phosphonate  Esters 
Effect of Phosphonate  Esters on Inhibition of C'la.--The inhibition of rat, rab- 
bit, and guinea pig C'la by the phenylalkyl phosphonates and by the chloro- 
alkyl phosphonates is seen in Fig.  2. The inhibition of rabbit C'la was deter- 
mined for this study, that of guinea pig C'la (25) and rat C'3a (3) from previous 404  IMMI,FNOLOGIC INJURY. II 
studies. Table IV shows the inhibition  of rabbit, rat,  and guinea pig C'la by 
pentyl, 5-aminopentyl, and 5-chloropentyl phosphonate. 
The great similarity in the patterns of inhibition of the enzymes from three 
different species is evident in Fig. 2 and Table IV. The only significant  difference 
TABLE III 
Role of C'4, C~3, and C'3 in Complement-Dependent Histamine Release by Rabbit AntLRGG 
Reagent* 
A. Normal serum 
0.5 u KSCN-serum 
B. 0.5 M  KSCN-serum 
C.  1.0 ~t KSCN-serum 
Component addvd$ 
84/zg C'4 
395 btg C'3 
84 gg C'4 +  395/.tg C'3 
84 #g C'4 
84 #g Cr4 +  494 gg C'3 
84 #g C'4 +  987 #g C'3 
84/zg C'4 +  1974/zg C'3 
151/zg C'4 +  884/zg C'3 
151/zg Cr4 +  884/zg C'3 +  104 
/~g C'5 
Histamine  Hemolytic 
releas______~e .titer  (CHs0) 
2  %  107 
{  o  {  <1 
0  <1 
0  <1 
12  89 
0  3 
9  69 
13  76 
13  82 
0  <1 
6  12 
* Normal  or 0.5 ~  KSCN-serum used in a final concentration  of 5% undiluted serum; 
1.0 M KSCN-serum used in a final concentration of 10% undiluted serum. 
Per ml of undiluted KSCN-serum. 
TABLE IV 
Inhibition of Rabbit, Rat, and Guinea Pig C'la by Pentyl, 5-Aminopentyl, and 
5-Chloropentyl Phosphonate 
Phosphonate ester 
Pentyl phosphonate 
5-aminopentyl phosphonate 
5-chloropentyl phosphonate 
Inhibition  (I~o) 
Rabbit Cqa  Rat C'la  Guinea  pig Cqa 
4.2  X  10  -8 
2.3  X  l0 s 
4.4  X  10  -3 
1.0  X  10  -3 
3.1  X  10  -6 
1.9  X  10  -a 
1.4  X  10  -8 
1.5  X  10  -~ 
3.5  X  10  -3 
is  that benzyl phosphonate  shows a  peak activity against  guinea  pig  C'la, 
whereas  the phenyl phosphonate gives maximal inhibition of rabbit and rat 
Cqa. 
Effect of Phosphonate Esters on Whole Hemolytic Complement Activity.--None 
of the phenylalkyl phosphonates or  the two chloroalkyl phosphonates which 
were tested inhibited the hemolytic activity of whole complement when used at K.  ~RANK  AUSTEN  AND  ELMER  L.  BECEER  405 
the limit of their solubility. The phenyl and benzyl phosphonates were employed 
in a final concentration of 3.0 X  10  .-3 ~, the phenylethyl at 6.7 X  10  -~ M, the 
phenylpropyl at 4.0 X  10  -~ M, and the 3-chloropropyl and 4-chlorobutyl phos- 
phonates at 2.0 X  10  -8 u. The 5-amlnopentyl phosphonate was inhibitory with 
an I's0 of 4.2 X  10  -~r. 
Dose-Response Curves  for Phospkonate Ester Inhibition of Complement-depend- 
4.0 
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NUMBER  OF  CARBON  ATOMS  IN  ALKYL  CHAIN 
FIG.  2.  The  variation  in  effectiveness  of  inhibitory  activity  of  the p-nitrophenyl ethyl 
phenylalkyl phospbonates (A)  and the p-nitrophenyl  ethyl  chloroalkyl phosphonates  (B) 
against rabbit C'la, rat C~la, and guinea pig C'la. 406  IMMUNOLOGIC  INJURY.  II 
ent Histamine Release by Rabbit  A nti-RGG.--The same  10  compounds  com- 
in  the non-complement requiring,  homocytotropic antibody-mediated release 
of histamine  (3)  were  studied  for their  effect on  the  complement-dependent 
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FIG. 3. The effect of concentration of phenyl, benzyl, 3-chloropropyl, 5-chloropentyl, and 
5-aminopentyl phosphonates on their ability to inhibit complement-dependent, noncytotoxic 
histamine release. 
reaction.  Dose-response curves of only 5  compounds were investigated,  since 
these compounds had already been shown to be functionally free of impurity (3). 
Fig. 3 shows the linear relation of per cent inhibition of histamine release to 
the concentration of phenyl, benzyl, 3-chloropropyl, 5-chloropentyl, and 5-ami- 
nopentyl phosphonate. The release of histamine from sensitized mast cells incu- K. FRANK  AUSTEN  AND  ELMER  L. BECKER  407 
bated with the phosphonate esters in the absence of added rabbit serum did not 
increase with increasing concentrations of these phosphonate esters. 
Lack of Inhibitory Effect of Phosphonate Esters When Added to and Removed 
from Rabbit Serum or Sensitized  Cells before Interaction  of Serum and Sensitized 
Cdts.--In the first group of experiments, the effect of the phosphonates on se- 
rum in the absence of sensitized mast cells was tested. 100th ml of phenyl, 5- 
aminopentyl,  and 4-chlorobutyl phosphonate  in  acetone was  added  to  1 ml 
samples of normal rabbit serum at a final concentration of 3 X  10  -~, 4 X  10-", 
and 9 X  10  -~ x~ respectively. The mixtures of serum and phosphonate were in- 
cubated for 20 min at 37°C and gradually turned yellow from the p-nltrophenyl 
liberated by the enzymatic breakdown of the phosphonate ester (23). For a con- 
trol 0.01 ml of acetone was added to 1  ml normal rabbit serum and treated in 
TABLE  V 
Effea of Exposing Rabbit Serum to the Phosphonate Esters on the Subsequent Capacity of Such 
Serum to Rdease Histamine 
Treatment of rabbit serum*  Histamine release 
A. Acetone 
5-aminopentyl phosphonate 
B. Freshly thawed 
Acetone 
4-chlorobutyl phosphonate 
phenylpropyl phosphonate 
% 
41 
38 
36 
36 
36 
36 
* Rabbit serum treated with phosphonate, dialyzed, and used to release histamine from 
sensitized mast ceUs as described in Materials and Methods. 
the same way. At the end of 20 rain, the serum samples were dialyzed in the cold 
for 6 hr against 3 changes of glucose-free Tyrode's buffer to remove unreacted 
phosphonate. As seen in Table V, none of the phosphonate ester inhibitors af- 
fected the histamine-releasing capacity of the rabbit serum when removed prior 
to adding the serum to the sensitized mast cells. These same phosphonates gave 
75 to 90 % inhibition when present in these concentrations at the time serum was 
added to sensitized cells. 
In order to test the effect of these inhibitors on the mast cells, sensitization 
by Ra anfi-RGG was carried out in their presence. Sensitization in the presence 
or absence of the phosphonate esters was allowed to proceed for 3 man at 37°C, 
and then the cells were sedimented, washed, resuspended, and exposed to fresh 
normal rabbit serum in the usual manner. As seen in Table VI, there was no 
interference with histamine release. 
These results indicate that the phosphonate esters act only on an antigen- 408  IMMUNOLOGIC  INJURY.  II 
antibody-activated esterase which appears following interaction of the sensi- 
tized mast cells and normal rabbit serum. 
The Effect of Structure on the Activity of the Pkosphonate Inhibitors.--Fig. 4, A 
demonstrates that the degree of inhibition given by the phenylalkyl phospho- 
hates increases regularly with increasing distance of the benzene ring from the 
phosphorous atom. In the chloroalkyl series  (Fig. 4, B), the inhibitory activity 
increased regularly with increasing chain length for the entire series tested; i.e., 
from the 2-chloroethyl to the 5-chloropentyl phosphonates. Both the 5-chloro- 
pentyl and 5-aminopentyl phosphonates were superior to the pentyl phospho- 
hate in preventing histamine release (Table VII). 
Most of the studies analyzing the role of complement components in hista- 
mine release were done with human reagents and purified human components. 
It was therefore necessary to be certain that the same relationship of phospho- 
nate structure to inhibition of histamine release was observed with human as 
TABLE VI 
Effect of Exposing Mast Cells to the Phosphonate Esters During the Sensitization Step 
Chemical present during sensitization procedure*  Histamine release 
Acetone 
5-aminopentyl  phosphonate 
4-chlorobutyl  phosphonate 
Phenylpropyl  phosphonate 
% 
49 
48 
48 
48 
* Mast cells sensitized with Ra anti-RGG in the presence of various phosphonate esters 
as described in Materials and Methods; histamine released by the subsequent addition of 
normal rabbit serum in the usual final concentration of 5% undiluted serum. 
with rabbit complement. Two pairs of phosphonate esters, chosen to provide a 
critical comparison, were used. As seen in Table VIII, the phenylethyl was dis- 
tinctly better than the benzyl phosphonate, and the 5-chloropentyl was superior 
to the 4-chlorobutyl phosphonate as an inhibitor of histamine release from sen- 
sitized mast cells by human serum. These are the same relationships observed 
when rabbit serum is used as the complement source (Table VIII and Fig. 4). 
Effect of Enzymatic Hydrolysis of the Phos  phonates by Rabbit Serum.--Hydrol- 
ysis of the phosphonate esters by the mast cells  is negligible and can be disre- 
garded. Rabbit serum, however, contains an enzyme which hydrolyzes the phos- 
phonates (23). The resulting ethoxy phosphonic acids are inactive as inhibitors. 
It was also necessary to be certain that the relationship of structure to inhibi- 
tory activity observed was not due in part to differences in the relative suscep- 
tibility of the phosphonates to enzymatic inactivation by rabbit serum. The 
concentrations of the phosphonates used were the highest employed in the study 
of their activity against histamine release. K. FRANK  AUSTEN  AND ELMER  L. BECKER 
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FIG. 4. The effect  of structure of the p-nitrophenyl ethyl phenylalkyl phosphonates (A) 
and the p-nitrophenyl ethyl chloroalkyl phosphonates (B) on their ability to inhibit comple- 
ment-dependent, noncytotoxic histamine release. 
TABLE VII 
Inhibition  o/ Complement-Dependent  Histamine Release by Pentyl, 5-Aminopentyl, 
and 5-Chloropentyl Phosphonate 
Phosphonate ester  Inhibition (/%o) 
M 
Pentyl phosphonate  7.0  X  10  --4 
5-aminopentyl  phosphonate  2.1 X  10  --4 
5-chloropenty] phosphonate  2.8  X  10  -4 410  rMMUNOLOGIC INJURY. II 
In the phenylalkyl series the phenyl phosphonate was hydrolyzed most rap- 
idly (5.5 X  10  -5 ~/liter/5 rain) and the benzyl phosphonate least rapidly; the 
phenylpropyl was broken down faster than the phenylethyl phosphonate. These 
results make it impossible for the differential rates of hydrolysis to be respon- 
sible for the pattern of inhibition of histamine release given by the phenylalkyl 
phosphonate series. Furthermore, the hydrolysis rate of even the most suscep- 
tible member, the phenyl phosphonate, was not sufficient to be of significance 
in the inhibition experiments. 
In  the  chloroalkyl series,  the  2-chloroalkyl was  hydrolyzed most  rapidly 
(7.2 10  -4 ~r/liter/5 min), and the 3-chloropropyl phosphonate the least rapidly. 
This pattern, as well as the rates, makes it impossible for hydrolysis to contrib- 
ute to the pattern of inhibition of histamine release by the chloroalkyl phospho- 
nate series. 
TABLE VIII 
Comparison of Human and Rabbit Serum as Complement Sources on the Inhibition of Histamine 
Release by Phosphonate Esters 
Phosphonate ester  Human serum (I'5o)  Rabbit  serum (I'6o) 
Benzyl phosphonate 
Phenylethyl phosphonate 
4-chlorobutyl  phosphonate 
5-chloropentyl  phosphonate 
M 
9.5  X  10  -4 
4.0  X  10  -4 
4.8  X  10  -4 
2.6  X  10  -4 
M 
5.9 X 10  -4 
3.2 X 10  -4 
4.9 X 10  -4 
2.7 X 10  -4 
DISCUSSION 
The data presented  herein on the complement-dependent  release  of histamine 
by rabbit anti-RGG are concerned  with both the number  of complement  com- 
ponents involved and the character of the antigen-antibody  activated, phos- 
phonate-sensitive esterase required for histamine release. The observations  on 
these two points will be discussed separately and then integrated into a single 
reaction scheme. 
Requirement for Complement Components.--There  is an absolute requirement 
for C'I, C'2, C'4, C'3, and C'S in releasing histamine from rat peritoneal  mast 
cells sensitized  with Ra anti-RGG.  This conclusion  is based  upon the restoration 
of histamine-releasing capacity by adding highly purified complement  compo- 
nents to sera deficient  in one or more  of these components  (Tables  I to III, Fig. 
I). Of special advantage was the availability of sera from  humans and rabbits 
with inborn or acquired  deficiencies  in a single component  of complement. 
With the addition of highly  purified  human C~2 (Fig. I) to serum genetically 
deficient  in this  component,  there was a linear relationship  between  the number 
of hemolytic C'2 units added and the percentage of histamine released from K. FRANK  AUSTEN  AND  ELMER  L. BECKER  411 
sensitized mast cells. There was also a reasonable correspondence between the 
restoration of histamine-releasing and hemolytic capacity of nephritic sera by 
the addition of highly purified human C'3 (Table II). The correlation between 
restoration of hemolytic activity and histamine-releasing capacity of the C~2  - 
and C'3-deficient sera rests upon the fact that these natural reagents are defi- 
cient in only a single complement component (15, 16). 
In contrast, the artificially prepared R  reagents are both incompletely de- 
pleted of the desired component and partially deficient in many others. The 
partial deficiency of components other than the desired one is seen clearly in the 
results obtained with the R1 reagent (Table I). The R1 alone gave neither his- 
tamine  release  nor  hemolytic  activity with  cells  in  the  MAgAbC'la  hu  or 
EAC'la  hu state, respectively. The R1 had to be fortified with heated serum or 
purified components, CP4, C~3, and C'5, before demonstrating histamine-releas- 
ing or hemolytic activity. 
Direct reconstitufion of an R1 +  H  reagent with purified human CPla pre- 
pared from the subcomponents failed to relase histamine from sensitized mast 
cells. Restoration was only effective when C'la was already present on the sen- 
stitized mast cell. Completely analogous results are obtained when Cqa is added 
to an R1 in the presence of EA (7, 26). The ability of fluid phase Ctla to inac- 
tivate CP4 and Ct2 in the R1 reagent explains the failure to restore complement 
activity with this experimental design. 
The incomplete depletion of a desired component was observed in attempts 
to prepare an R2 reagent. An R2 prepared either by dialysis (14) or by dilution 
(14, 19) was invariably found to contain 10 to 15 % of the initial C'2 concentra- 
tion, 60 to 90 units per ml of the equivalent undiluted serum when assayed with 
EAC'la*~, 4~ cells (19, 27). Reference to Fig. 1 demonstrates that this amount 
of C~2 is sufficient to give full histamine-releasing activity. This is undoubtedly 
the explanation for the finding of Keller (5) that an R2 reagent sustains hista- 
mine release. 
With recognition of their shortcomings, certain artificially prepared reagents 
were used to demonstrate a requirement for certain complement components in 
histamine release from sensitized mast cells. With the addition of purified com- 
ponents (Table III) it was possible to demonstrate an association between his- 
tamine-releasing and hemolytic capacity. 
The ability of serum from complement-deficient rabbits to sustain histamine 
release by rabbit anti-RGG was reported by Keller (5); in Keller's experiments 
it is possible that C% supplied with the antiserum reconstituted the deficient 
serum since both were added simultaneously. In the present experiments, cells 
were sensitized with rabbit anti-RGG and washed twice before being exposed 
to serum from rabbits genetically deficient in C'6 (6, 28). The results were not 
consistent; in  early experiments  the  deficient sera were  active,  but in later 
experiments using subsequent bleedings or sera from different donors,  there 412  IMMUNOLOGIC  INJURY.  II 
was no activity. Any judgment as to a  requirement for C'6 in the release of 
histamine from mast cells sensitized with rabbit anti-RGG must be deferred 
until experiments can be performed with deficient serum before and after recon- 
stitution with functionally pure rabbit C%. A definitive investigation as to the 
role of C'6 could best be carried out by preparing the sensitized mast cell com- 
plement intermediates in a fashion analogous to preparation of the sensitized 
red cell intermediates.The preparation of a sensitized mast cell in the MAgAbC/- 
la state (Table I) attests to the feasibility of this approach. 
Inhibition by Phosphonate Esters.--The inhibition of complement-dependent 
histamine release by the phosphonate esters is not through an irreversible effect 
on either the sensitized mast cell (Table VI) or serum complement (Table V) 
alone. Inhibition occurs only when the phosphonate is present at the time of 
interaction between the sensitized mast cell and serum complement. Thus, the 
phosphonate esters must inhibit an antigen-antibody-activated esterase which 
exists in a phosphonate resistant precursor form until activation by the inter- 
action of the sensitized cell and serum complement. 
There is almost a  complete disparity in the ability of the phenylalkyl and 
chloroalkyl phosphonates to inhibit the complement-dependent release of hista- 
mine (Fig. 4) and to inhibit Ctla (Fig. 2). It is clear that the inhibitory pattern 
given  by  the  phosphonates  in  complement-dependent histamine  release  by 
rabbit anti-RGG is not a reflection of the capacity of rabbit serum to inactivate 
the phosphonates by enzymatic hydrolysis. Moreover, the fact that both the 
hemolytic- and histamine-releasing reactions involve cell suspensions obviates 
the possibility that differences in accessibility of the inhibitor to the target cell 
plays an appreciable role. Even though C'la (Table I) is required for comple- 
ment-dependent histamine release by rabbit anti-RGG, this is not the esterase 
being blocked by the phosphonates when they inhibit this reaction. 
The failure of the phosphonate esters to block the Cqa involved in the coln- 
plement-dependent release of histamine is presumably on  the same basis  as 
their failure to prevent immune hemolysis by whole rabbit serum. At the rela- 
tively low dilution of rabbit serum used as a source of complement for histamine 
release or immune hemolysis, the rate of activation of C'lp to C'la exceeds the 
capacity of the phosphonate esters to inactivate sufficient C'la  to block the 
reactions at this point. On the other hand, immune hemolysis by whole guinea 
pig complement can be blocked because the higher whole complement activity 
of guinea pig serura permits greater dilution of C'la (25). As is evident from 
Fig.  2,  the prior activation of a  relatively limited amount of rabbit C'la,  as 
on  the  EAC~la  r~b, 4*p  cell,  permits  irreversible, progressive  inactivation  by 
the phosphonate esters. This suggests that a similar inhibition could be achieved 
by studying the effect of the phosphonates on histamine release from sensitized 
mast cells previously reacted with the first component of complement. 
The same straight line relationship between the concentration of phosphonate K.  FRANK  AUSTEN  AND  ELMER  L.  BECKER  413 
and per cent inhibition of histamine release is found in the complement-depend- 
ent,  noncytotoxic histamine  release  reaction  (Fig.  3) and in homocytotropic 
antibody-mediated histamine release  (reference 3, Fig. 3). This implies that in 
both reactions there is a critical step (s) subsequent to activation of the esterase 
which has the same mathematical dependence on the concentration of activated 
esterase. 
The pattern of inhibition by the phosphonates of the antigen-antibody-acti- 
vated esterase required for complement-dependent histamine release is remark- 
ably similar  to  that  of  the  esterase required for homocytotropic  antibody- 
mediated  histamine  release.  The  phenylalkyl  phosphonate  series  shows  the 
same increase in inhibitory potency with an increase in alkyl chain length in 
both  complement-dependent  (Fig.  4,  A)  and homocytotropic  antibody-me- 
diated (reference 3, Fig. 4, A) histamine release. The 5-aminopentyl and 5-chlo- 
ropentyl phosphonates were distinctly better inhibitors of both reactions (Table 
VII; reference 3,  Table IV)  than  the pentyl phosphonate.  In fact,  the only 
difference  in inhibition pattern between the two reactions was observed with 
the chloroalkyl series. In the complement-dependent histamine-releasing  reac- 
tion, there was a progressive increase in inhibitory activity in going from the 
2-chloroethyl to the 5-chloropentyl phosphonate  (Fig.  4,  B). The homocyto- 
tropic  antibody-mediated  release  of histamine  differed  from  this  insofar  as 
there was little or no difference in the activity of the 3-chloropropyl and 4-chlor- 
obutyl phosphonates (reference 3, Fig. 4, B) ; however, in going to the 5-chloro- 
pentyl phosphonate there was a further increase in inhibitory activity. With 
the many  similarities  in  the  pattern  of phosphonate  inhibition  of  the  two 
reactions,  the minor  difference  in  the  chloroalkyl phosphonate  series  is not 
considered significant. 
An increase in potency with an increase  in alkyl chain length of the phenyl- 
alkyl phosphonates is characteristic of the reaction of these phosphonates with 
chymotrypsin (29). With chymotrypsin there is also an increase in activity of 
the chloroalkyl series with increasing  chain length (30). Thus, the antigen-anti- 
body-activated  esterases involved  in  the  complement-dependent  release  of 
histamine  and in the homocytotropic antibody-mediated release of histamine 
resemble chymotrypsin in their reactivity with the phenylalkyt and chloroalkyl 
phosphonates.  They differ  from chymotrypsin in  their  greater  susceptibility 
to the 5-arninopentyl phosphonate relative to the pentyl phosphonate. 
The  Relationship  of  Complement-Dependent ttistamine  Release by  Rabbit 
Anti-RGG  to Homocytotropic Antibody-Mediated  Histamine  Release.--Lepow 
and Dias Da Silva (32) have shown that human  anaphylotoxin formed in a 
fluid phase reaction using purified  components can release histamine from rat 
peritoneal mast cells. Only the first four components of complement are re- 
quired to generate human anaphylotoxin.  Since the release  of histamine from 
rat peritoneal mast cells sensitized  with rabbif anti-RGG requires at least the 414  IM~XTNOLOGIC  INJURY.  II 
first five components of human complement, the latter reaction is probably not 
mediated by anaphylotoxin. 
The homocytotropic antibody-mediated release of histamine differs from the 
complement-dependent reaction in not needing complement and in requiring a 
unique rat immunoglobulin to sensitize the mast cell. This immunoglobulin is 
not rat IgG, IgM, of IgA (2). Presumably, the complement-dependent, noncyto- 
toxic reaction is initiated by an immune aggregate adsorbed to the target cell. 
Despite these differences there is a very great similarity in the pattern of inhibi- 
tion given by the phosphonate esters in blocking these two reactions. One pos- 
sible implication is that these two quite different modes of carrying out an an- 
tigen-antibody reaction on  the  rat mast  cell lead  to activation of the same 
esterase. It may be that these different ways of initiating histamine release have 
a  final common pathway. 
SI.IM~AR¥ 
There is an absolute requirement for C'I, C'2, C'4, C'3, and C'5 in releasing 
histamine from rat peritoneal mast cells sensitized with rabbit anti-rat gamma 
globulin. This conclusion is based upon the restoration of histamine-releasing 
capacity by adding highly purified complement components to sera deficient in 
one or more of these components. Of special advantage was the availability of 
sera from humans with inborn or acquired deficiencies in a single component. 
The p-nitrophenyl ethyl phosphonates block this reaction by inhibiting an 
antigen-antibody-activated esterase which exists in  a  phosphonate  resistant 
precursor state until activated by the interaction of the sensitized mast cell and 
serum complement. There is almost complete disparity between the ability of 
the phosphonates to inhibit complement-dependent histamine release by rabbit 
anfi-RGG and to inactivate C'la. Even though C'la is required for complement- 
dependent histamine release by rabbit anti-RGG, this is not the esterase being 
blocked by the phosphonates under the experimental conditions used. 
The pattern of inhibition by the phosphonates of the antigen-antibody-ac- 
tivated esterase required for complement-dependent, noncytotoxic histamine re- 
lease is remarkably similar to that of the esterase required for homocytotropic 
antibody-mediated histamine release. One possible implication is that these two 
quite different modes of carrying out antigen-antibody-induced histamine re- 
lease from rat peritoneal mast cells lead to activation of the same esterase and 
share a  common pathway. 
We acknowledge with gratitude the expert assistance given by Mrs. Cynthia Laitman 
Orenberg and Miss Barbara Moyer. We wish to express our thanks to Dr. I. H. Lepow and 
Dr. H. Mtiller-Eberhard  for their generosity  in providing us with highly purified complement 
components and to Dr. K. Rother for samples of serum from rabbits deficient in the sixth 
component of complement. K.  ]FRANK AUSTEN AND  ELMER L.  BECKER  415 
BIBLIOGRAPHY 
1.  Austen, K. F., and Bloch, K. J., Differentiation in vitro of antigen-induced hista- 
mine release from complement-dependent immune injury, Ciba Found. Syrup. 
Complement, 1965, 281. 
2.  Austen, K. F., Bloch,  K. J., Baker, A. R., and Arnason,  B. G., Immunological 
histamine release from rat mast cells in ~itro: Effect of age of cell donor,  Proc. 
Soc. Exp. Biol. and Med.,  1965, 120, 542. 
3.  Becker,  E.  L.,  and  Austen,  K.  F.,  Mechanisms  of immunologic  injury  of rat 
peritoneal mast cells.  I. The effect of phosphonate inhibitors  on homocyto- 
tropic antibody mediated release  and first component of rat complement, J. 
Exp. Med.,  1966, 124, 379. 
4.  Keller, R., Anaphylaxis in isolated rat mast cells. III. Localization of the chymo- 
trypsin-type protease in the heat labile serum components, Int. Arch. Allergy 
and Appl. Imrnunol., 1964, 24, 255. 
5.  Keller, R., Further evidence  of the existence  of differences in the mechanism of 
immune cellular injury of sheep erythrocytes and rat mast cells, Experimentia, 
1965, 9.1, 295. 
6.  Pother, K., Pother, U., Nilsson,  U., and Mtiller-Eberhard, H. J., manuscript in 
preparation. 
7.  Lepow, I. H., Naff, G. B., Todd, E. W., Pensky, J., and Hinz, C. F., Chromato- 
graphic resolution  of  the  first component of human  complement into  three 
activities, J. Exp. Med., 1963, 117, 983. 
8.  Naff, G. B.,  Pensky, J., and Lepow, I. H., The macromolecular nature  of the 
first component of human complement, J. Exp. Med.,  1964, 119, 593. 
9.  Lepow, I. I-I., Todd, E. W.,  Smink,  R. D., and Pensky, J., Purification of the 
second component (C~2) of human complement, Fed. Proc., 1965, 24, 446. 
10.  Policy, M. J., and Miiller-Eberhard, H. J., Isolation of the  second component of 
human complement and the effect of iodoacetamide on its activity, Fed. Proc., 
1965, 24, 446. 
11.  Nilsson,  U. R., and MfiUer-Eberhard,  H. J., Isolation of/~,-globulin from human 
serum and its characterization as the fifth component of complement, J. Exp. 
Med.,  1965, 19.2, 277. 
12.  Mfiller-Eberhard,  I-I. J.,  Dalmasso,  A.  P.,  and  Calcott,  M.  A.,  The  reaction 
mechanism of tiC-globulin  (C~3) in immune hemolysis,  J. Exp. Med.,  1966, 
123, 33. 
13.  Mfiller-Eberhard, H. J., and Biro,  C. E., Isolation and description of the fourth 
component of human complement, J. Exp. Med.,  1963, 118, 447. 
14.  Kabat, E. A., and Mayer, M. M., Experimental Immunochemistry, Springfield, 
Illinois,  Charles C. Thomas, 2nd edition,  1961, 133. 
15.  Klemperer, M. R., Woodworth, H. C., Rosen, F. S., and Austen, K. F., Heredi- 
tary deficiency of the second component of human complement, J. Clin. Inv., 
in press. 
16.  Klemperer, M. R.,  Gotoff,  S.  P., Alper,  C. A.,  Le~n, A.  S., and Rosen,  F.  S., 
Estimation of the serum file globulin  concentration: its relation to the serum 
hemolytic complement titer, Pediatrics, 1965, 35, 765. 416  ]-~UNOLOGIC INJ'U'RY. II 
17.  Rother,  U.,  and  Rother, K., Uber einen  angeborenen  Komplement-Defekt bei 
Kaninchen, Z. Immunit~tsforsch,  1961, 19.1, 224. 
18.  Dalmasso, A. P., and Miiller-Eberhard, H. ]., Complement activity in lipid-free 
human serum,  in  Complement  Workshop,  La ]olla, California,  1966. 
19.  Austen,  K. F., and Beer, F., The measurement of second component of human 
complement  (C'2 hu) by its interaction with EAC'la  gp, 4*p ceils, J. Immunol., 
1964, 9"2, 946. 
20.  Nelson,  R. A., The role of complement in immune phenomena, in The Inflam- 
matory Process, (B. W. Zweifach, L.  Grant, and R. T. McCluskey,  editors), 
New York, Academic Press, 1965, 819. 
21.  Austen, K. F., and Russell, P. S., Detection of renal allograft rejection in man by 
demonstration of a reduction in the serum  concentration of the second com- 
ponent of complement, Ann. New York Acad. Sc., 1966, in press. 
22.  Kent, J. F., Bukantz, S. C., and Rein,  C. R., Studies in complement fixation. I. 
Spectrophotometric titration of complement;  construction of graphs for direct 
determination of the 50% hemolytic unit, J. Immunol., 1946, 53, 37. 
23.  Becket, E. L., Punte, C. L., and Barbaro, J. F., The enzymatic hydrolysis of p- 
nitrophenyl ethyl phosphonates  by mammalian  plasma,  Biochem. Pharmacol., 
1964, 13, 1219. 
24.  Becket, E. L., The possible significance of a particular group of serine esterases in 
pathological  permeability changes, in Mechanism  of Ceil and Tissue Damage 
Produced by Immune Reactions,  (P. Grabar and P. Miescher, editors),  Basel, 
Benno Schwabe and Co., 1962, 37. 
25.  Becket, E. L., and Austen,  K. F., A comparison  of the specificity of inhibition 
by phosphonate esters of the first component of complement and the antigen- 
induced release of histamine from guinea pig lung, J. Exp. Med., 1964, 120, 491. 
26.  Becker, E. L., Concerning  the mechanism  of complement  action.  IV. The prop- 
erties  of activated first  component of guinea  pig  complement,  J.  Immunol., 
1959, 82, 43. 
27.  Austen, K. F., personal communication. 
28.  Rother, K., The nature of a hereditary deficiency of the rabbit complement sys- 
tem, in Complement Workshop, La Jolla,  California, 1966. 
29.  Becket, E. L., Fukuto, T. R., Boone, B.,  Canham,  D.  C., and Boger, E., The 
relationship  of  enzyme inhibitory activity to  the  structure  of  n-alkylphos- 
phonates and  phenylalkylphosphonate esters,  Biochemistry,  1963, 9.,  72. 
30.  Boone, B., and Becker, E. L., Enzyme inhibitory activity of certain phosphonate 
esters  against  chymotrypsin, trypsin, and  acetyl cholinesterase,  Biochem. et 
Biophysica Acta, 1964, 85, 441. 
31.  Dias Da Silva, W., and Lepow, I. H., Anaphylotoxin formation by purified human 
C'I esterase, J. Immunol.,  1965, 95, 1080. 
32.  Lepow, I. H., and Dias Da Silva, W., Properties of anaphylotoxin prepared from 
purified  components  of human  complement,  in  Complement  Workshop,  La 
Jolla,  California, 1966. 